Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Tyler W. Buckner, Craig Kessler, Giancarlo Castaman, Cédric Hermans, Victor Jimenez-Yuste, Johnny Mahlangu, Wolfgang A. Miesbach, Johannes Oldenburg, Michael Recht, Leonard A. Valentino, Allison P Wheeler, Steven W. Pipe

Blood (2024) 144 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2024-194935

Published: 2024

Journal Articles

ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B

Fernando F Corrales-Medina, Nana Ama Afari-Dwamena, Amanda B. Blair, Shannon L Carpenter, Tammuella Chrisentery-Singleton, Nabil Daoud, Maissaa Janbain, Leslie Raffini, Jonathan Schwartz, Ayesha Zia, Michael Recht

Blood (2024) 144 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2024-198548

Published: 2024

Journal Articles

Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data

Michael Recht, Hanna Salehi, Chris Blazos, Sophie Lai, Ella Morton, Lucy Lee, Juliana M.L. Biondo, Janet S Lee

Blood (2024) 144 (Supplement 1): 5078.

https://doi.org/10.1182/blood-2024-200784

Published: 2024

Journal Articles

Comparison of Projected Hemophilia a Populations Residing in Hospital Referral Regions with and without Hemophilia Treatment Centers in the US

Maria E. E Santaella, Karina Raimundo, Robert Schuldt, Michael Recht

Blood (2023) 142 (Supplement 1): 3696.

https://doi.org/10.1182/blood-2023-181009

Published: 2023

Journal Articles

Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores

Tyler W. Buckner, Nabil Daoud, Lucy Lee, Elise Lim, Jonathan Schwartz, Karina Raimundo, Michael Recht

Blood (2023) 142 (Supplement 1): 3998.

https://doi.org/10.1182/blood-2023-174092

Published: 2023

Journal Articles

Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy

Blood (2023) 142 (Supplement 1): 1056.

https://doi.org/10.1182/blood-2023-186891

Published: 2023

Journal Articles

Real-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset

Martin Chandler, Jessica Charlet, Thomas Moulton, Michael Recht

Blood (2023) 142 (Supplement 1): 5479.

https://doi.org/10.1182/blood-2023-188995

Published: 2023

Journal Articles

Walking the Walk: Inclusion of Lived Experience Experts in the Design of the National Hemophilia Foundation's National Research Blueprint for Those Living with Inherited Bleeding Disorders

Maria E. E Santaella, Samantha Carlson, LMSW, Donna DiMichele, Keri Norris, Sammie Valadez, Leonard A. Valentino, Esmeralda Vazquez, Michelle Witkop, Michael Recht

Blood (2023) 142 (Supplement 1): 7216.

https://doi.org/10.1182/blood-2023-186109

Published: 2023

Journal Articles

Athn Transcends Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia

Tammuella Chrisentery-Singleton, Carrie O'Neill, Catherine Rea, Jigar Amin, Michael Recht

Blood (2023) 142 (Supplement 1): 5457.

https://doi.org/10.1182/blood-2023-190090

Published: 2023

Journal Articles

Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset

Brian Hu, Martin Chandler, Matthew Manuel, Jorge Caicedo, Michael Denne, Bruce Ewenstein, Ali Mokdad, Shan Xing, Michael Recht

Blood (2022) 140 (Supplement 1): 2722–2723.

https://doi.org/10.1182/blood-2022-163861

Published: 2022

Journal Articles

Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset

Martin Chandler, Jessica Charlet, Thomas Moulton, Michael Recht

Blood (2022) 140 (Supplement 1): 2751–2752.

https://doi.org/10.1182/blood-2022-166669

Published: 2022

Journal Articles

National Hemophilia Foundation Champions a National Research Blueprint Defining a Community-Coordinated Research Ecosystem to Accelerate Progress in Inherited Bleeding Disorders

Michelle Witkop, Maria E. Santaella, Michael Recht, Keri Norris, Brett Spitale, Esmeralda Vasquez, Donna DiMichele, Kevin Mills

Blood (2022) 140 (Supplement 1): 5021–5022.

https://doi.org/10.1182/blood-2022-170842

Published: 2022

Journal Articles

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand, Martin Chandler, Carol Fedor, Michael Recht, Robert F. Sidonio, Jr.

Blood (2022) 140 (Supplement 1): 5600–5602.

https://doi.org/10.1182/blood-2022-163302

Published: 2022

Journal Articles

Durability of Factor IX Activity and Bleeding Rate in People with Severe or Moderately Severe Hemophilia B after 5 Years of Follow-up in the Phase 1/2 Study of AMT-060, and after 3 Years of Follow-up in the Phase 2b and 2 Years of Follow-up in the Phase 3 Studies of Etranacogene Dezaparvovec (AMT-061)

Wolfgang A. Miesbach, Michael Recht, Nigel S. Key, Krupa Sivamurthy, Paul E. Monahan, Steven W. Pipe

Blood (2022) 140 (Supplement 1): 4913–4914.

https://doi.org/10.1182/blood-2022-166810

Published: 2022

Journal Articles

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, Michiel Coppens, David Cooper, Robert Gut, Sergio Slawka, Stephanie Verweij, Ricardo Dolmetsch, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach

Blood (2022) 140 (Supplement 1): 4910–4912.

https://doi.org/10.1182/blood-2022-166135

Published: 2022

Journal Articles

Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, Nigel S. Key, Susan Lattimore, Giancarlo Castaman, David Cooper, Stephanie Verweij, Ricardo Dolmetsch, Jacqueline Tarrant, Yanyan Li, Paul E. Monahan, Wolfgang A. Miesbach

Blood (2022) 140 (Supplement 1): 4904–4906.

https://doi.org/10.1182/blood-2022-166745

Published: 2022

Journal Articles

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

Shannon L Carpenter, Martin Chandler, Michael F Guerrera, Lynn Malec, Matthew Manuel, Michael Recht, Ulrike Reiss, Robert F. Sidonio, Jr., Cristina Tarango, Marijke Van den Berg, Michael Wang, Courtney D. Thornburg

Blood (2022) 140 (Supplement 1): 63–64.

https://doi.org/10.1182/blood-2022-162660

Published: 2022

Journal Articles

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Tammuella Chrisentery-Singleton, Lauren E. Amos, Daniel Bonzo, Miguel Escobar, Adam Giermasz, Emmanuelle Lagrue, Christine Knoll, Sonia Nasr, Michael Recht, Spencer Sullivan, Doris V. Quon, Mark T. Reding

Blood (2022) 140 (Supplement 1): 11360–11361.

https://doi.org/10.1182/blood-2022-163372

Published: 2022

Journal Articles

Characterization of Bleeding and Laboratory Phenotype of Carriers of Hemophilia and Trends of Utilization of Factor Concentrates and Hemostatic Therapies: Analysis of the National Athndataset

Neeraja Swaminathan, Brian Hu, Alison Currie, Roshni Kulkarni, Steven W. Pipe, Michael Recht, Peter A. Kouides, Anjali Sharathkumar

Blood (2022) 140 (Supplement 1): 59–60.

https://doi.org/10.1182/blood-2022-158861

Published: 2022

Journal Articles

Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0

Marquita Decker-Palmer, Susan Mathias, Hilary Colwell, Ross Crosby, Brittany Gentile, Janet Chupka, Robert F. Sidonio, Jr., Michael Recht, Amy D. Shapiro, James Zazzali

Blood (2022) 140 (Supplement 1): 11328–11329.

https://doi.org/10.1182/blood-2022-157932

Published: 2022

NARROW

Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B

Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data

Comparison of Projected Hemophilia a Populations Residing in Hospital Referral Regions with and without Hemophilia Treatment Centers in the US

Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores

Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy

Real-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset

Walking the Walk: Inclusion of Lived Experience Experts in the Design of the National Hemophilia Foundation's National Research Blueprint for Those Living with Inherited Bleeding Disorders

Athn Transcends Natural History Cohort Study of Bleeding Symptoms and Treatment Outcomes in Patients with Glanzmann Thrombasthenia

Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset

Real-World Use of Octocog Alfa and Damoctocog Alfa Pegol in Women with Hemophilia a from the ATHNdataset

National Hemophilia Foundation Champions a National Research Blueprint Defining a Community-Coordinated Research Ecosystem to Accelerate Progress in Inherited Bleeding Disorders

Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)

Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Characterization of Bleeding and Laboratory Phenotype of Carriers of Hemophilia and Trends of Utilization of Factor Concentrates and Hemostatic Therapies: Analysis of the National Athndataset

Performance of the Comprehensive Assessment Tool for Challenges in Hemophilia (CATCH) 2.0

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only